NCT00602641
Clinical Trial Information
Trial Number: NCT00602641 (ClinicalTrials.gov)
Disease Type:
- Hematopoietic Neoplasm/Myeloma - Myeloma
Trial Title:
An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid™) (MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy
Study ID:
E1A06
Images are available?:
No
Is this a NCI-MATCH Trial?:
No
Datasets Linked to Trial
| Title | Description |
|---|---|
| NCT00602641-D3 | There are three different submissions (each for one dataset) for trial NCT00602641. This data submission, NCT00602641-D3, contains toxicity data. The other two data submissions, NCT00602641-D1 and NCT00602641-D2, contain clinical data together with QOL data and data for treatment dose, respectively. |
| NCT00602641-D2 | There are three different submissions (each for one dataset) for trial NCT00602641. This data submission, NCT00602641-D2, contains data for treatment dose. The other two data submissions, NCT00602641-D1 and NCT00602641-D3, contain clinical data together with QOL data and toxicity data, respectively. |
| NCT00602641-D1 | There are three different submissions (each for one dataset) for trial NCT00602641. This data submission, NCT00602641-D1, contains clinical data together with QOL data. The other two data submissions, NCT00602641-D2 and NCT00602641-D3, contain data for treatment dose and toxicity, respectively. |
Accessibility | Disclaimer | FOIA | HHS Vulnerability Disclosure | Privacy & Security
U.S. Department of Health and Human Services | National Institutes of Health | National Cancer Institute | USA.gov
NIH…Turning Discovery Into Health®